Press Releases - Emmaus Medical, Inc.

Michigan Revises Prior Authorization Criteria for Endari®December 10, 2020

Emmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.

Emmaus Life Sciences Launches Endari® Support ProgramDecember 08, 2020

Emmaus Life Sciences, Inc., announced today the launch of the Endari® Support Program.

Endari® Granted Orphan Drug Status in SwitzerlandDecember 03, 2020

Emmaus Life Sciences, Inc., announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®.

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®November 10, 2020

Emmaus Life Sciences, Inc., announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain.

FDA Approves Updated Label for Endari®November 03, 2020

Emmaus Life Sciences, Inc., announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.